ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1386

Olokizumab in Real Clinical Practice: Efficacy and Safety

Sofia Kuzkina1, Alena Zagrebneva2, Galym Togizbayev3, Elvira Aitova4, Nataliya Belozerova5, Irina Patrikeeva6, Ruzana Samigullina7, Mikhail Sostak7, Evgeniya Jakovleva8, Anton Chudinov9, Antonina Dolgorukova10, Evgeniy Alekseev11 and EVGENY NASONOV12, 1R-Pharm, Moscow, Russia, 2Clinical hospital #52, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Clinic of Bashkir State Medical University, Ufa, Russia, 5SBIHC «Region clinic hospital Nr 2»; SBEA HE «Kuban state medical university»,, Krasnodar, Russia, 6GBUZ Tyumen Regional Clinical Hospital N 1, Tyumen, Russia, 7North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia, 8Scientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1, Krasnodar, Russia, 9Clinical Rheumatology Hospital No.25; North-West State Medical University named after I.I.Mechnikov, Saint-Petersburg, Russia, 10R-Pharm, JSC, Moscow, Russia, 11R-Pharm, JSC, Saint-Petersburg, Russia, 12V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University, Moscow, Russia

Meeting: ACR Convergence 2024

Keywords: Biologicals, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: RA – Treatment Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Olokizumab (OKZ) is a direct inhibitor of interleukin 6, which has shown significant symptom reduction in RA patients, however there is a lack of information regarding the use of olokizumab in real clinical practice. Here we report efficacy and safety of olokizumab in routine practice.

Methods: It was a retrospective 24 weeks observational program in 63 centers including RA patients, who received OKZ (64 mg once every 4 weeks or every 2 weeks subcutaneous). The efficacy was assessed by routine clinical, biochemical parameters, DAS28-ESR, CDAI.  Descriptive statistics – mean and standard deviation, absolute and relative frequencies were used. The paired t-test and the chi-square test were used to evaluate the statistical significance. A difference was considered statistically significant at p< 0.05. All AEs were recorded.

Results: 1880 patients with RA were included in the observational program. 1018 of them received OKZ at least 24 weeks by 31.03.2024. Female patients predominated (82.2%). The average age of the patients was 53.2(13.4) years. The average duration of RA was 119.4 (87.9) months. 85.5% of patients had from 1 to 8 comorbid conditions. Most patients were RF (85.6%) and ACCP (81.4%) positive. 330(32.4%) patients had previously taken another bDMARD (tsDMARD) therapy. The average duration of taking the last bDMARD(tsDMARD) was 30.1(32.1) months. Reasons for switching to OKZ included inefficacy (56.7%), non-medical reasons related to the availability of drugs (27.6%), AEs (11.2%), others (4.5%). 57.3% patients were initially received steroids at an average dose of 7.2(4.0) mg/day.
OKZ treatment for 24 weeks led to a significant decrease in the DAS28-ESR and CDAI indices. Remission or low activity according to the DAS28-ESR were achieved by 69.7% of patients, according to the CDAI – by 55.1% of patients (Figure). Number of patients receiving steroid therapy reduced by 53,0% and the average dose decreased to 4.7(2.4) mg/d (compared to baseline p< 0.001).
Therapy was discontinued in 27(2.6%) patients due to lack of efficacy. AEs were recorded in 52(5.1%) patients, including MACE in 2(0.2%) patients. AEs led to interruption of OKZ therapy in 30(2.9%) patients (Table).

Conclusion: In real clinical practice olokizumab significantly improves the symptoms of RA, and in some cases allows stopping steroid therapy. Olokizumab did not cause additional safety concerns.

Supporting image 1

Figure. RA Efficacy Indices at Baseline and 24 Weeks of Therapy

Supporting image 2


Disclosures: S. Kuzkina: R-Pharm, 3; A. Zagrebneva: Biocad, 6, R-Pharm, JSC, 6; G. Togizbayev: R-Pharm, 5; E. Aitova: R-Pharm, JSC, 6; N. Belozerova: R-Pharm, JSC, 6; I. Patrikeeva: Biocad, 6, Novartis, 6, R-Pharm, JSC, 6, Swixx, 6; R. Samigullina: Biocad, 6, R-Pharm, JSC, 6; M. Sostak: Biocad, 6, R-Pharm, JSC, 6; E. Jakovleva: R-Pharm, JSC, 3; A. Chudinov: R-Pharm, JSC, 6; A. Dolgorukova: R-Phrm, JSC, 3; E. Alekseev: R-Pharm, JSC, 3; E. NASONOV: None.

To cite this abstract in AMA style:

Kuzkina S, Zagrebneva A, Togizbayev G, Aitova E, Belozerova N, Patrikeeva I, Samigullina R, Sostak M, Jakovleva E, Chudinov A, Dolgorukova A, Alekseev E, NASONOV E. Olokizumab in Real Clinical Practice: Efficacy and Safety [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/olokizumab-in-real-clinical-practice-efficacy-and-safety/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/olokizumab-in-real-clinical-practice-efficacy-and-safety/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology